<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04026360</url>
  </required_header>
  <id_info>
    <org_study_id>SCILD</org_study_id>
    <nct_id>NCT04026360</nct_id>
  </id_info>
  <brief_title>Impact of Early Lung Physiology, Viral Infections and the Microbiota on the Development and Progression of Lung Disease in Children With Cystic Fibrosis</brief_title>
  <acronym>SCILD</acronym>
  <official_title>Impact of Early Lung Physiology, Viral Infections and the Microbiota on the Development and Progression of Lung Disease in Children With Cystic Fibrosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Children's Hospital, Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire Vaudois</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kantonsspital Aarau</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Children's Hospital Basel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Inselspital, Berne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study collects data on microbiological factors and lung function parameters (e.g.&#xD;
      spirometry, body plethysmography, lung-MRI) to assess their interaction on the lung growth&#xD;
      and lung development of infants and children with Cystic Fibrosis (CF).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background:&#xD;
&#xD;
      Cystic fibrosis (CF) is the most common lethal inherited disease in North European&#xD;
      populations, affecting approximately 1:2500 live births. It is a multisystem disorder with&#xD;
      respiratory morbidity and mortality being the leading cause of death. Lung disease in CF is&#xD;
      characterized by neutrophil-dominated inflammation and chronic bacterial infection of the&#xD;
      airways, which results in deterioration of lung function and premature death [1]. Despite&#xD;
      improved survival in successive birth cohorts, the current median survival age of patients&#xD;
      with CF is about 40 years [2]. Understanding the initiating events of CF lung disease (e.g&#xD;
      viral infections and microbiome) and their influence on disease progression throughout early&#xD;
      childhood is essential to improve survival through targeted early interventions.&#xD;
&#xD;
      Objectives:&#xD;
&#xD;
      The overarching aim of this study is to identify early life predictors of disease progression&#xD;
      in children with CF. Therefore, this study implies three objectives, as follows: i) to&#xD;
      investigate the effect of respiratory viral infections on microbiota dynamics in the first&#xD;
      year of life in infants with CF, and to examine their influence on lung function at 1 year of&#xD;
      age; ii) to examine whether deficits in lung function in the first year of life in infants&#xD;
      with CF persist to pre- and school age and adolescence and are associated with impaired&#xD;
      functional and structural abnormalities at 3, 6, 9, 12, 15 and 18 years of age; and iii) to&#xD;
      determine the principal drivers of impaired lung function at 1 year and impaired lung&#xD;
      function and structural outcomes at 3, 6, 9, 12, 15 and 18 years of age in individuals with&#xD;
      CF.&#xD;
&#xD;
      Methods:&#xD;
&#xD;
      Lung function, magnetic resonance imaging (MRI), respiratory symptoms and quality of life&#xD;
      questionnaires, microbiology, medical history and clinical data will be collected during each&#xD;
      phase of the study.&#xD;
&#xD;
      Recruitment and participation:&#xD;
&#xD;
      Infants with CF diagnosed by NBS will be recruited at the time of their first lung function&#xD;
      test in Bern at the age of 4-8 weeks. As part of the protocol for the diagnosis and follow-up&#xD;
      of CF infants diagnosed by NBS, which has been implemented by the Task Force for CF NBS on&#xD;
      behalf of the Swiss Working Group for Cystic Fibrosis, optional infant lung function at the&#xD;
      University Children's Hospital of Bern is proposed to all parents of newly diagnosed CF&#xD;
      infants.&#xD;
&#xD;
      Information collected:&#xD;
&#xD;
      Lung function data:&#xD;
&#xD;
        -  Tidal breathing parameters (minute ventilation, respiratory rate, tidal volume, tidal&#xD;
           expiratory flow, tidal inspiratory flow, time to peak expiratory flow) averaged over 100&#xD;
           breaths&#xD;
&#xD;
        -  Multiple breath washout (FRC, LCI, moment ratios) and single breath washout (molar mass)&#xD;
&#xD;
        -  Spirometric forced expiratory volume loops (FVC, FEV1, PEF, MEF50)&#xD;
&#xD;
        -  Body plethysmography (airway resistance, lung volumes: TLC, FRC, RV)&#xD;
&#xD;
        -  Respiratory Rate over 60 seconds&#xD;
&#xD;
        -  Fractional exhaled nitric oxide (marker of airway inflammation)&#xD;
&#xD;
        -  Resistance interrupter measurement&#xD;
&#xD;
        -  Electric nose&#xD;
&#xD;
        -  Forced oscillation technique&#xD;
&#xD;
        -  Electrical impedance tomography&#xD;
&#xD;
        -  Impedance plethysmography&#xD;
&#xD;
      Microbiological data:&#xD;
&#xD;
        -  Nasal swabs (respiratory virus and bacterial diagnostics, as well as host transcriptome&#xD;
           analysis)&#xD;
&#xD;
        -  Pharyngeal swabs (bacterial colonization and microbiota analysis)&#xD;
&#xD;
        -  Sputum (to analyse the neutrophils)&#xD;
&#xD;
      Blood count (hemoglobin concentration, hematocrit, leukocyte number, lymphocyte number,&#xD;
      lymphocyte count, eosinophil count, basophil count, monocyte count, promyelocyte count,&#xD;
      myelocyte count, platelet count, immunoglobulin E level, interleukins,&#xD;
      Granulocyte-Monocyte-Colony Forming Unit, Tumor Necrosis Factor alpha, Interferon gamma and&#xD;
      Interferon lambda)&#xD;
&#xD;
      Urine (to estimate the tobacco exposure during pregnancy (amount of Cotinine) and the content&#xD;
      of caffeine and steroid profile)&#xD;
&#xD;
      Lung MRI:&#xD;
&#xD;
      Functional and structural images of the lung&#xD;
&#xD;
      Skin-Prick Test (test for pollen, trees, house dust mite, cat and dog)&#xD;
&#xD;
      Questionnaires (to assess quality of life)&#xD;
&#xD;
      Medical history (information on respiratory symptoms, pulmonary exacerbations,&#xD;
      hospitalisations and regular therapy)&#xD;
&#xD;
      Study database:&#xD;
&#xD;
      All study data is recorded in an Access-database with SQL Servers by electronic Case Report&#xD;
      Forms. The database is accordant to the HFG and was adapted together with the CTU.&#xD;
&#xD;
      Funding:&#xD;
&#xD;
      Schweizerischer Nationalfonds (SNF), Schweizerische Gesellschaft f√ºr Cystische Fibrose&#xD;
      (CFCH), Departement Lehre und Forschung des Inselspitals Bern&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2011</start_date>
  <completion_date type="Anticipated">December 31, 2050</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2050</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Multiple Breath Washout</measure>
    <time_frame>Every third year from the age of 4-8 weeks/1 year till 18 years.</time_frame>
    <description>Longitudinal assessment of lung volume and ventilation inhomogeneity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Spirometry</measure>
    <time_frame>Every third year from the age of 4-8 weeks/1 year till 18 years.</time_frame>
    <description>Longitudinal assessment of long volumes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Body plethysmography</measure>
    <time_frame>Every third year from the age of 4-8 weeks/1 year till 18 years.</time_frame>
    <description>Longitudinal assessment of ventilation inhomogeneity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Magnetic Resonance Imaging (MRI)</measure>
    <time_frame>At the age of 4-8 weeks, 1, 3, 6, 9, 12, 15 and 18 years</time_frame>
    <description>Longitudinal assessment of regional lung perfusion and ventilation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Nasal swabs</measure>
    <time_frame>At the age of 4-8 weeks, 1, 3, 6, 9, 12, 15 and 18 years</time_frame>
    <description>Longitudinal assessment of viral and bacterial colonization of the nasal swab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Weekly swabs</measure>
    <time_frame>Weekly from the visit at the age of 4-8 weeks till the age of 1 year</time_frame>
    <description>Respiratory virus and bacterial diagnostic</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Swabs during respiratory infection</measure>
    <time_frame>From the visit at the age of 4-8 weeks till the age of 1 year</time_frame>
    <description>Respiratory viruses and Bacteria, changes of the microbial flora</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Routine swabs in CF</measure>
    <time_frame>At the age of 4-8 weeks, 1 year and at each 3-monthly clinic visit during the age of 3, 6, 9, 12, 15 and 18 years</time_frame>
    <description>Longitudinal assessment of bacterial changes, changes of the resistome (genes conferring antibiotic resistance) and the changes of the microbial flora</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Respiratory Rate (RR)</measure>
    <time_frame>From the visit at the age of 4-8 weeks till the age of 1 year</time_frame>
    <description>The number of breaths over 60 seconds</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sweat test</measure>
    <time_frame>At the age of 3, 6, 9, 12, 15 and 18 years</time_frame>
    <description>Sweat Chloride concentration</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Confirmed Diagnosis of Cystic Fibrosis</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention</intervention_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Oropharyngeal swabs&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Cystic Fibrosis Patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Infants with a confirmed diagnosis of CF by NBS&#xD;
&#xD;
          -  Age &lt;=18 years&#xD;
&#xD;
          -  Written informed consent by patient and/or parent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Need for respiratory support for more than three days&#xD;
&#xD;
          -  Severe malformations or known diseases other than CF&#xD;
&#xD;
          -  Maternal drug abuse&#xD;
&#xD;
          -  Known severe maternal disease&#xD;
&#xD;
          -  Severe Problems of communication&#xD;
&#xD;
          -  Pacemaker, continuous glucose monitor&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philipp Latzin, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Children's Hospital Bern</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Philipp Latzin, MD PhD</last_name>
    <phone>0041 31 632 94 93</phone>
    <email>philipp.latzin@insel.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Children's Hospital Bern</name>
      <address>
        <city>Bern</city>
        <zip>3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philipp Latzin, MD PhD</last_name>
      <phone>0041 31 632 94 93</phone>
      <email>philipp.latzin@insel.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>May 14, 2019</study_first_submitted>
  <study_first_submitted_qc>July 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2019</study_first_posted>
  <last_update_submitted>November 3, 2020</last_update_submitted>
  <last_update_submitted_qc>November 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Infants</keyword>
  <keyword>Cystic Fibrosis</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Microbiome</keyword>
  <keyword>Airway growth</keyword>
  <keyword>Airway development</keyword>
  <keyword>Genetic predisposition</keyword>
  <keyword>Tobacco</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

